AECI categories included: increased AST (16.2%), increased ALT (14.6%), increased blood bilirubin (12.2%), rash (11.7%), hypothyroidism (10.4%), anemia (8.4%), hyperthyroidism (5.5%), fever (4.4%), diarrhea (4.0%), injection site reactions (4.0%), proteinuria (4.0%), abnormal hepatic function (3.3%), increased blood thyroid-stimulating hormone (3.1%), hyponatremia (2.7%), and pruritus (2.7%). This evidence concerns the gene GPT and Hyponatremia.